Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Clinical-phase2-trials-NASH-and-obesity Clinical-phase2-trials-NASH-and-obesity Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Arti-cell Forte stem cell-based veterinary product Arti-cell Forte stem cell-based veterinary product Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
Groundbeaking of vaccine production center in France Groundbeaking of vaccine production center in France Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Emmanuelle leads a team of scientists Emmanuelle leads a team of scientists Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.
BI X colleague about working with purpose BI X colleague about working with purpose Ding works on an app that gives patients remote access to stroke rehabilitation via their mobile phones and tablets
biolabs-heidelberg biolabs-heidelberg Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Boehringer Ingelheim good 2021 business performance Boehringer Ingelheim good 2021 business performance 2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim announces appointments to Board of Managing Directors
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
A future without pills – could AI change the way we treat psychiatric diseases? A future without pills – could AI change the way we treat psychiatric diseases? Dr Cornelia Dorner-Ciossek talks about how her work with smartphone tech could transform how we treat mental illness.
Boehringer Ingelheim reaches more patients than ever, innovation drives growth Boehringer Ingelheim reaches more patients than ever, innovation drives growth Boehringer Ingelheim reports a strong performance in 2022.
cat feline diabetes medication treatment eu approval cat feline diabetes medication treatment eu approval Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
Veterinary oncology - cancer treatment Veterinary oncology - cancer treatment Our R&D team's efforts toward finding new cancer treatments for pets
NEJM-IL-36-Phase-1-GPP-data NEJM-IL-36-Phase-1-GPP-data Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
Algorithms to battle heartworm disease Algorithms to battle heartworm disease Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Boehringer Ingelheim Venture Fund invests precision antimicrobials Boehringer Ingelheim Venture Fund invests precision antimicrobials Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials